Medical treatment of juvenile idiopathic arthritis

JAMA

Volumn 294, Issue 13, 2005, Pages 1671-1684

  Hashkes, Philip J ^a   Laxer, Ronald M ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DICLOFENAC; ETANERCEPT; FENOPROFEN; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; ROFECOXIB; SALAZOSULFAPYRIDINE; SULINDAC; TOLMETIN;

CARDIOTOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; DISORIENTATION; DRUG EFFICACY; DUODENITIS; DYSPHORIA; EMBASE; GASTRITIS; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY PAPILLA NECROSIS; LEUKOPENIA; MEDLINE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 26044469891     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.13.1671     Document Type: Review

References (159)

1. Manners PJ, Bowers C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol. 2002;29:1520-1530.
2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392.
3. Wallace CA, Sherry DD. Rudolph's Pediatrics. Juvenile rheumatoid arthritis. In: 21st ed. New York, NY: McGraw-Hill; 2003:836-837.
4. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am. 1991;17:891-905.
5. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study II: outcome. J Rheumatol. 1995;22:308-319.
6. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. 1997;40:2235-2240.
7. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology. 2000;39:198-204.
8. Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000;43:1858-1865.
9. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491-496.
10. Minden K, Niewerth M, Listing J, et al. Longterm outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:2392-2401.
11. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989-1999.
12. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean follow-up of 10 years. J Rheumatol. 2003;30:579-584.
13. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology. 2002;41:1428-1435.
14. Foster HE, Marshall N, Myers A, Dunklet P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767-775.
15. Mayer ML, Sandborg CI, Mellins ED. Role of pediatric and internist rheumatologists in treating children with rheumatic diseases. Pediatrics. 2004;113:e173-e181.
16. Levinson JE, Baum J, Brewer E Jr, Fink C, Hanson V, Schaller J. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1977;91:799-804.
17. Makela AL. Naproxen in the treatment of juvenile rheumatoid arthritis: metabolism, safety and efficacy. Scand J Rheumatol. 1977;6:193-205.
18. Bhettay E, Thomson AJ. Double-blind study of ketoprofen and indomethacin in juvenile chronic arthritis. S Afr Med J. 1978;54:276-278.
19. Brewer EJ, Giannini EH, Baum J, et al. Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial: a segment II study. J Rheumatol. 1982;9:123-128.
20. Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol. 1983;12:325-330.
21. Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single-center 24-week double-blind parallel study. Scand J Rheumatol. 1984;13:342-350.
22. Bhettay E. Double-blind study of sulindac and aspirin in juvenile chronic arthritis. S Afr Med J. 1986;70: 724-726.
23. Williams PL, Ansell BM, Bell A, et al. Multicenter study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol. 1986;25:67-71.
24. Garcia-Morteo O, Maldonado-Cocco JA, Cuttica R, Garay SM. Piroxicam in juvenile rheumatoid arthritis. Eur J Rheumatol Inflamm. 1987;8:49-53.
25. Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol. 1988;6:157-160.
26. Giannini EH, Brewer EJ, Miller ML, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1990;117:645-652.
27. Kiss MH, Reiff AA, Reicin AS, et al. J. Rofecoxib demonstrates efficacy and tolerability in children and adolescents (ages 2-17 years) with juvenile rheumatoid arthritis (JRA) in a 12-week randomized study [abstract]. Arthritis Rheum. 2003;48(suppl):S650.
28. Gedalia A, Espada G, Johnson P, Kovacs B, Wood C, Padula S; Meloxicam in JRA Study Group. Efficacy and safety of meloxicam oral suspension in the treatment of juvenile rheumatoid arthritis (JRA): results from a twelve-week active-controlled (naproxen oral suspension), multinational trial [abstract]. Arthritis Rheum. 2004;50(suppl):S95.
29. Ruperto N, Nikishina I, Pachanov ED, et al. A randomized double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563-572.
30. Kvien TK, Hoyeraal HM, Sandstad B. Gold sodium thiomalate and D-penicillamine: a controlled, comparative study in patients with pauciarticular and polyarticular juvenile rheumatoid arthritis. Scand J Rheumatol. 1985;14:346-354.
31. Kvien TK, Hoyeraal HM, Sandstad B. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol. 1985;12:533-539.
32. Prieur AM, Piussan C, Manigne P, Bordigoni P, Griscelli C. Evaluation of D-penicillamine in juvenile chronic arthritis: a double-blind, multicenter study. Arthritis Rheum. 1985;28:376-382.
33. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986;314:1269-1276.
34. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986;13:118-123.
35. Giannini EH, Brewer EJ Jr, Kuzmina N, Shaikov A, Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR doubleblind, placebo-controlled trial. Arthritis Rheum. 1990;33:466-476.
36. Hoza J, Kadlecova T, Nemcova D, Havelka S. Sulfasalazine and Delagil: a comparative study in patients with juvenile chronic arthritis. Acta Univ Carol [Med]. 1991;37:80-83.
37. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.- U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043-1049.
38. Picco P, Gattorno M, Buoncompagni A, et al. 6-Methylprednisolone "mini-pulses": a new modality of chronic glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheumatol. 1996;25:24-27.
39. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized double-blind, placebo-controlled, multicenter study: Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41:808-816.
40. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of lowdose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849-1857.
41. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191-2201.
42. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655-1666.
43. Balogh Z, Ruzsonyi E. Triamcinolone hexacetonide versus betamethasone: a double-blind comparative study of the long-term effects of intra-articular steroids in patients with juvenile chronic arthritis. Scand J Rheumatol. 1987;67(suppl):80-82.
44. Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology. 2003;42:1254-1259.
45. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004;43:1288-1291.
46. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol. 1994;21:2353-2358.
47. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol. 1996;23:919-924.
48. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-769.
49. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-1209.
50. Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol. 1992;19(suppl 33):6-10.
51. Gylys-Morin VM, Graham TB, Blebea JS, et al. Knee in early juvenile rheumatoid arthritis: MR imaging findings. Radiology. 2001;220:696-706.
52. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330-2334.
53. Savolainen HA, Isomaki HA. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1201-1203.
54. French AR, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Increased mortality in adults with a history of juvenile rheumatoid arthritis: a population based study. Arthritis Rheum. 2001;44:523-527.
55. Thomas E, Symmonds DP, Brewster DH, Black RJ, Macfarland GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30:958-965.
56. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology. 2001;40:1285-1292.
57. Ferucci ED, Majka DS, Parrish LA, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:239-246.
58. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000;43:2402-2409.
59. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398-1407.
60. Koren G, Pastusak A. Medical research in infants and children in the eighties: analysis of rejected protocols. Pediatr Res. 1990;27:432-435.
61. Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Pediatr Clin North Am. 1995;42:1099-1125.
62. Lovell DJ, Giannini EH, Brewer EJ Jr. Time course of response to nonsteroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum. 1984;27:1433-1437.
63. Goodman S, Howard P, Haig A, Flavin S, Macdonald B. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. J Rheumatol. 2003;30:829-831.
64. Laxer RM, Silverman ED, St-Cyr C, Tran MT, Lingam G. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther. 1988;10:381-387.
65. Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1149-1151.
66. Dowd JE, Cimaz R, Fink CW. Nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum. 1995;38:1225-1231.
67. Mulberg AE, Linz C, Bern E, et al. Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr. 1993;122:647-649.
68. Mehta S, Lang B. Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:2252-2254.
69. De Silva B, Banney L, Uttley W, et al. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol. 2000;17:480-483.
70. Szer IS, Goldenstein-Schainberg C, Kurtin PS. Paucity of renal complications associated with nonsteroidal antiinflammatory drugs in children with chronic arthritis. J Pediatr. 1991;119:815-817.
71. Malleson PN, Lockitch G, Mackinnon M, Mahy M, Petty RE. Renal disease in chronic arthritis of childhood a study of urinary N-acetyl-beta-glucosaminidase and beta 2-microglobulin excretion. Arthritis Rheum. 1990;33:1560-1566.
72. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol. 1998;25:1995-2002.
73. Kimura Y, Fieldston E, Devries-Vandervlugt B, et al. High dose, alternate day corticosteroids for systemic-onset juvenile rheumatoid arthritis. J Rheumatol. 2000;27:2018-2024.
74. Padeh S, Passwell JH. Intraarticular corticosteroid injections in the management of children with chronic arthritis. Arthritis Rheum. 1998;41:1210-1214.
75. Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr. 1995;127:317-321.
76. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol. 2000;27:2696-2702.
77. Ravelli A, Manzoni SM, Viola S, Pistorio A, Ruperto N, Martini A. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol. 2001;28:2100-2102.
78. Neidel J, Boehnke M, Kuster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:1620-1628.
79. Cleary AG, Murphy HD, Davidson JE. Intraarticular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:192-196.
80. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2507-2512.
81. Hagelberg S, Magnusson B, Jenner G, Andersson U. Do frequent corticosteroid injections in the knee cause cartilage damage in juvenile chronic arthritis? long-term follow-up with MRI. J Rheumatol. 2000;27(suppl 58):95.
82. Takken T, Van Der Net J, Helders PJ. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev. 2001;3:CD003129.
83. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991;3:297-302.
84. Ravelli A, Ramenghi B, Di Fuccia G, et al. Factors associated with response to methotrexate in systemiconset juvenile chronic arthritis. Acta Paediatr. 1994;83:428-432.
85. Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr. 1999;135:316-320.
86. Harel L, Wagner-Weiner L, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:1370-1374.
87. Ravelli A, Viola S, Ramenghi B, Beluffi G, Zonta LA, Martini A. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr. 1998;133:262-265.
88. Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100:994-997.
89. Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63:206-208.
90. Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1574-1576.
91. Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol. 1995;22:1570-1573.
92. Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate in juvenile chronic arthritis. Clin Exp Rheumatol. 1998;16:181-183.
93. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31:179-182.
94. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983;43:2342-2345.
95. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. J Rheumatol. 1997;24:2230-2232.
96. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999;17:625-627.
97. Passo MH, Hashkes PJ. Use of methotrexate in children. Bull Rheum Dis. 1998;47:1-5.
98. Ortiz-Alvarez O, Morishita K, Avery G, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2004;31:2501-2506.
99. Hashkes PJ, Balistreri WF, Bove KE, et al. The longterm effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:2226-2234.
100. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum. 1998;41:381-391.
101. Hashkes PJ, Balistreri WF, Bove KE, et al. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1999;134:47-52.
102. Cron RQ, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998;132:901-902.
103. Schmeling H, Stephan V, Burdach S, Horneff G. Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy. Z Rheumatol. 2002;61:168-172.
104. Muzaffer MA, Schneider R, Cameron B, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1996;128:698-700.
105. Falcini F, Taccetti G, Ermini M, et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:175-178.
106. Padeh S, Sharon N, Schiby G, et al. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol. 1997;24:2035-2037.
107. Londino AV Jr, Blatt J, Knisely AS. Hodgkin's disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol. 1998;25:1245-1246.
108. Krugmann J, Sailer-Hock M, Muller T, Gruber J, Allerberger F, Offner FA. Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol. 2000;31:253-255.
109. Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child. 2002;86:47-49.
110. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993;23:34-46.
111. Moroldo MB, Giannini EH. Estimates of the discriminant ability of definitions of improvement for juvenile rheumatoid arthritis. J Rheumatol. 1998;25:986-989.
112. Giannini EH, Brewer EJ, Kuzmina N, Alekseev L, Shokh BP. Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. Arthritis Rheum. 1988;31:15-20.
113. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol. 2001;28:845-853.
114. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, Goycochea-Robles MV. A 26 week randomized double-blind placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies [letter]. Ann Rheum Dis. 2002;61:941-942.
115. Silverman E, Spiegel L, Hawkins D, et al. Longterm open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:554-562.
116. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24:2436-2443.
117. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford). 2001;40:907-913.
118. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750-754.
119. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol. 1999;26:898-903.
120. Buriot D, Prieur AM, Lebranchu Y, et al. Acute leukemia in 3 children with chronic juvenile arthritis treated with chlorambucil. Arch Fr Pediatr. 1979;36:592-598.
121. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis. J Pediatr. 2004;145:856-857.
122. Ravelli A, Moretti C, Temporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:569-572.
123. Shaikov AV, Maximov AA, Speransky AI, Lovell DJ, Giannini EH, Solovyev SK. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a longterm study. J Rheumatol. 1992;19:612-616.
124. Lovell DJ, Giannini EH, Reiff A, et al. Longterm efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing, multicenter, openlabel, extended-treatment trial. Arthritis Rheum. 2003;48:218-226.
125. Lovell D, Reiff A, Jones OY, Schneider R, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy experience with etanercept (Enbrel) in children with polyarticular juvenile rheumatoid arthritis [abstract]. Arthritis Rheum. 2004;50(suppl):S436.
126. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638-1644.
127. Russo RAG, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:723-726.
128. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-1101.
129. Kimura Y, Li S, Ebner-Lyon L, Imundo L. Treatment of systemic JIA (JRA) with etanercept: results of a survey [abstract]. Arthritis Rheum. 2000;43(suppl):S257.
130. Kimura Y, Pinho P, Higgins G, et al. Treatment of systemic onset juvenile rheumatoid arthritis (SOJRA) with etanercept - a follow-up study [abstract]. Arthritis Rheum. 2002;46(suppl):S481.
131. Horneff G, Schmeling H, Moebius D, Foeldvari I. Efficacy of etanercept in active refractory juvenile spondyloarthropathy: prospective open study of 40 patients [abstract]. Arthritis Rheum. 2004;50(suppl): S91.
132. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthropathy. Arthritis Rheum. 2005;52:2103-2108.
133. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2001;28:1677-1680.
134. Horneff G, Girschick H, Michels H, Rogalski B, Schmeling H. Factors associated with failure of etanercept therapy in systemic onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum. 2004;50(suppl): S93.
135. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020-1030.
136. Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43:527-529.
137. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
138. Livermore PA, Murray KJ. Anti-tumor necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford). 2002;41:1450-1452.
139. Lepore L, Marchetti F, Facchini S, Leone V, Ventura A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21:276-277.
140. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:2606-2608.
141. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
142. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645-646.
143. Vinje O, Obiora E, Forre O. Juvenile chronic polyarthritis treated with infliximab [abstract]. Ann Rheum Dis. 2000;59:25.
144. Vougiouka O, Rizou S, Grafakou O. Infliximab or etanercept in the treatment of juvenile idiopathic arthritis: the Athens experience [abstract]. Ann Rheum Dis. 2001;60:176.
145. Masatlioglu S, Gogus F, Cevirgen D, et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis [abstract]. Arthritis Rheum. 2002;46:S481.
146. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: on open label study. Ann Rheum Dis. 2003;62:245-247.
147. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistent active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005;52:548-553.
148. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and predictive model. Aliment Pharmacol Ther. 2003;17:75-84.
149. Lovell DJ, Ruperto N, Goodman S, et al. Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA) [abstract]. Arthritis Rheum. 2004;50(suppl):S436.
150. Ilowite NT, Porras O, Reiff A, et al. A twelve-week open label safety and efficacy study of anakinra (Kineret) in juvenile rheumatoid arthritis [abstract]. Ann Rheum Dis. 2003;62(suppl 1):87.
151. Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum. 2004; 50(suppl):S437.
152. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-1486.
153. Uziel Y, Laxer RM, Schneider R, Silverman ED. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol. 1996;23:910-918.
154. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996;39:623-628.
155. Pignatti P, Vivarelli M, Meazze C, Rizzolo MG, Martini A, de Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670-1676.
156. Ogilvie EM, Fife MS, Thompson SD, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003;48:3202-3206.
157. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818-825.
158. Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet. 1999;353:550-553.
159. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004;63:1318-1326.